Klinische Forschergruppe 228 - Immunopathogenesis and Therapy of Glomerulonephritis

Glomerulonephritis as a disease category is one of the leading causes of end-stage renal disease in the Western world and is associated with significant morbidity and mortality. Glomerulonephritis represents a heterogeneous collection of disease entities. However, fundamental to each form of glomerulonephritis is the immune-mediated renal damage which consists of a specific immune reaction followed by an effector phase of inflammation. This pathophysiological concept is the current rationale for unspecific immunosuppressive therapy with corticosteroids and cytotoxic agents. The missing specificity of these therapeutic regimes, however, and their frequently disabling side effects are the main reasons for the urgent need to develop new and more specific individual therapeutic strategies.

This Clinical Research Group will bring together scientists with a strong expertise in human and experimental glomerulonephritis (U. Panzer, F. Thaiss, O.M. Steinmetz, C. Meyer-Schwesinger and R. Stahl), in cellular immunology (H-W. Mittrücker, C. Kurts and G. Tiegs) and in renal pathology (H. Hopfer, T. Wiech and U. Helmchen). Using state-of-the-art techniques including renal in vivo imaging and (transgenic) animal models, combined with prospective studies in a large cohort of patients with glomerulonephritis, this Clinical Research Unit seeks to better understand the immunopathogenesis of human and experimental glomerulonephritis. These experimental approaches will help to identify, characterize and validate new diagnostic, prognostic and therapeutic targets in human glomerulonephritis.

Termine / Veranstaltungen

Keine Veranstaltungen gefunden.